COUR Pharma Closes $50M Series B for Immune Tolerance

Fundraise Insider tracks newly funded startups each week and delivers verified B2B leads list of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

COUR Pharma, a clinical-stage biotechnology company based in Skokie, Illinois, has closed a $50 million Series B round. The financing, announced on June 18, 2026, was led by existing investors Lumira Ventures and Roche Venture Fund, with new investor Sanofi joining the round.

Several existing backers also took part, including Alpha Wave Ventures, Pfizer Ventures, Angelini Ventures, and the T1D Fund, a Breakthrough T1D venture effort. The presence of pharmaceutical heavyweights like Roche, Sanofi, and Pfizer Ventures points to the strategic interest in the company’s underlying science.

COUR develops first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases. The central idea is to reprogram the immune system so it stops attacking the body’s own tissue, an approach that differs from broadly suppressing immune activity. The company’s work is built on a proprietary nanoparticle platform designed to deliver that antigen-specific tolerance.

The proceeds will support the clinical advancement of CNP-103, an investigational therapy developed using that nanoparticle platform. Moving a candidate through clinical trials is capital-intensive, and the $50 million gives the company room to push CNP-103 forward.

Autoimmune disease has been a difficult area for drug developers, in part because many existing treatments work by dampening the immune system as a whole, which can leave patients vulnerable to other problems. By aiming for a more targeted form of tolerance, COUR is pursuing a path that could sidestep some of those tradeoffs. With fresh funding and a roster of major pharmaceutical investors behind it, the Illinois company is set to keep developing its lead program.